Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR

Apellis director Dunlop A. Sinclair reported disposing of all reported equity interests in connection with the company’s merger with Biogen. Tendered common shares were exchanged for $41.00 in cash per share plus one CVR per share, with up to an additional $4.00 per share contingent on milestones. Vested options below $41 were cash-settled and converted into CVRs, while options at or above $45 were cancelled without consideration.

Analysis

This is a clean event-driven arb cleanup, not a fundamental read-through on the biotech complex. The economic value is now largely capped by the fixed cash leg, while the CVR shifts the remaining upside into a binary, milestone-driven instrument that will trade more like a litigation/royalty claim than like ordinary equity. That means post-close price action in APLS should be dominated by residual CVR probability and time value, not by operating headlines.

For BIIB, the acquisition is strategically modest but operationally useful: it adds an approved asset with potential downside insurance via the CVR, but it does not materially change the company’s growth curve unless the milestones hit. The more important second-order effect is capital allocation discipline — if BIIB pays up for optionality here, investors will judge whether this is an accretive tuck-in or a distraction from its core neurology/franchise pipeline. Any disappointment in CVR realization would likely be absorbed by the buyer, while any positive surprise would mainly benefit former APLS holders rather than re-rate BIIB.

The key risk is not the merger itself; it is milestone timing and enforceability. CVRs tend to suffer from spread compression after close, then reprice sharply on either milestone progress or negative calendar drift over the next 6–24 months. If the market is overestimating the probability of the full $4.00, the CVR should decay faster than implied by headline merger value, creating a potential short opportunity; if the milestones are genuinely near-term and auditable, the opposite holds and the CVR becomes a crowded long.

The contrarian view is that this may be less about takeover premium and more about a forced monetization of a complex, low-signal biotech story into a cleaner cash-plus-option payout. That usually benefits sophisticated holders who can price the CVR, but it can also create forced selling from investors unable to hold contingent paper. The likely inefficiency is in the post-close CVR, where retail and index-driven holders overpay for optionality or underprice the probability-weighted cash recovery.

Key Decisions for Investors

• If accessible, buy the APLS CVR only on post-close weakness and only as a small optionality sleeve; target a 6–18 month horizon and require at least 2:1 upside to expected probability-weighted payout.
• Short any over-the-counter CVR print that trades materially above conservative milestone probability; use this as a calendar decay trade if the milestones are not expected within 12 months.
• For event-driven books, pair long BIIB vs short a biotech ETF basket for 1–3 months if the market initially treats the deal as strategic accretion; the alpha is in BIIB avoiding a multiple de-rate, not in outright re-rating.
• Avoid chasing APLS common after close; the equity has been converted into a capped cash instrument plus CVR, so residual upside is mostly already monetized and the risk/reward is poor unless you have a direct view on milestone probability.